Investigation of improvement of sarcopenia by suppression of hyperammonemia with rifaximin.

Investigation of improvement of sarcopenia by suppression of hyperammonemia with rifaximin. - Investigation of improvement of sarcopenia by suppression of hyperammonemia with rifaximin.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048778

Enrollment

Registered

2022-08-28

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic patient

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Fasting blood ammonia level 2) Normal cognitive function 3) Child Pugh score of 9 or less 4)Patients expected to survive at least 12 months 5)Independent in ADL.

Exclusion criteria

Exclusion criteria: 1) Patients with liver cancer in more advanced stage than BCLC-C stage 2) Patients who will be treated for hepatocellular carcinoma within the study period. 3) Patients with serious bone or muscle disease or cardiac, pulmonary, renal, or cerebrovascular disease. 4) Pregnant or lactating women and patients who may or intend to become pregnant.

Design outcomes

Primary

Measure	Time frame
Grip strength after 12 weeks of rifaximin administration	—

Secondary

Measure	Time frame
Skeletal muscle index after 12 weeks of rifaximin administration	—

Countries

Japan

Contacts

Public ContactKei Endo

Iwate Medical University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine.

keiendo@iwate-med.ac.jp+81196137111

Outcome results